Tulathromycin (Draxxin)

Tulathromycin, marketed under the brand name Draxxin, is a triamilide macrolide antibiotic that has become one of the most widely used antimicrobials in cattle and swine respiratory disease management. Developed specifically for veterinary use, tulathromycin offers a unique pharmacokinetic profile characterized by rapid absorption, extensive tissue distribution, and prolonged pulmonary concentrations that support single-dose treatment protocols. The drug has gained widespread acceptance in the livestock industry due to its efficacy, convenience, and favorable safety profile in both cattle and swine, distinguishing it from some older macrolides with more restrictive species limitations.

The mechanism of action of tulathromycin involves binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and preventing bacterial replication. As a triamilide, tulathromycin contains three nitrogen atoms in its chemical structure, which contributes to its unique pharmacokinetic properties, particularly its extensive accumulation in lung tissue and pulmonary macrophages. This tissue-targeting characteristic is fundamental to the drug's efficacy against respiratory pathogens and explains why therapeutic activity is maintained for extended periods following a single injection despite declining plasma concentrations.

Tulathromycin is available as a sterile injectable solution at a concentration of 100 mg/mL, formulated for single-dose administration. The subcutaneous route is used in cattle, while intramuscular injection is the approved route in swine. A combination product containing tulathromycin with ketoprofen (Draxxin KP) is also available, providing both antimicrobial and anti-inflammatory effects for cattle with respiratory disease accompanied by pyrexia. The standard Draxxin formulation appears as a clear, colorless to pale yellow solution and should be examined before use to ensure no visible changes have occurred.

From a regulatory perspective, tulathromycin has FDA approval for both cattle and swine, providing important versatility for operations that house multiple species. Indications include treatment and control of bovine respiratory disease in cattle, treatment and control of swine respiratory disease in pigs, and treatment of infectious bovine keratoconjunctivitis (pinkeye) in cattle. The drug requires a veterinary prescription and must be used within the context of a valid veterinarian-client-patient relationship. Specific restrictions apply to certain classes of cattle, including prohibitions on use in female dairy cattle 20 months of age or older.

The primary indication for tulathromycin in cattle is the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis. BRD is the most economically significant disease in the cattle industry, causing billions of dollars in annual losses through mortality, treatment costs, reduced performance, and decreased carcass value. Tulathromycin's broad spectrum of activity against these key pathogens, combined with its convenient single-dose administration, has made it a mainstay of BRD treatment protocols in feedlots, stocker operations, and cow-calf enterprises throughout North America and beyond.

Beyond treatment of clinical disease, tulathromycin carries an important indication for the control of respiratory disease in cattle at high risk of developing BRD. This metaphylactic application is particularly valuable during the high-risk receiving period when newly arrived cattle face the combined challenges of transportation stress, commingling, dietary changes, and exposure to novel pathogens. By administering tulathromycin to at-risk populations upon arrival, veterinarians can significantly reduce both the incidence and severity of respiratory disease outbreaks. Studies have consistently demonstrated that metaphylactic tulathromycin reduces morbidity, mortality, and retreatment rates in high-risk cattle populations.

Tulathromycin is also approved for the treatment of infectious bovine keratoconjunctivitis (IBK), commonly known as pinkeye, caused by Moraxella bovis. Pinkeye is a painful and economically important eye disease of cattle that can lead to corneal ulceration, scarring, and blindness if untreated. The efficacy of tulathromycin against M. bovis provides an important treatment option for this condition, particularly in situations where topical or subconjunctival treatments are impractical. The systemic administration approach is advantageous for range cattle or large groups where individual handling for eye treatments is challenging.

In swine, tulathromycin is approved for the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae. These organisms represent the major bacterial contributors to respiratory disease losses in swine production. The single-dose administration is well-suited to swine production systems where group treatment efficiency is important. Additionally, tulathromycin is approved for the control of SRD in groups of swine at high risk of developing respiratory disease, providing metaphylactic options similar to those available in cattle.

Extra-label use of tulathromycin may be considered by veterinarians when approved indications do not precisely address the clinical situation at hand. Any extra-label use must comply with AMDUCA requirements, including the existence of a valid VCPR, documentation that no approved drug is labeled for the use, appropriate record-keeping, and assignment of extended withdrawal periods. Extra-label use should be based on sound veterinary judgment regarding the likelihood of efficacy and the appropriateness of the drug for the specific organism and disease condition.

The approved dosage of tulathromycin for cattle is 2.5 mg per kilogram of body weight (2.5 mg/kg), administered as a single subcutaneous injection. Using the 100 mg/mL formulation, this translates to 1 mL per 40 kilograms (88 pounds) of body weight. Accurate weight determination or estimation is essential for proper dosing to ensure therapeutic efficacy while avoiding unnecessary overdosing. In feedlot settings, cattle are typically sorted into weight groups, and dosing is calculated based on average group weight or individual assessment for animals requiring treatment.

For swine, the approved dosage is also 2.5 mg per kilogram of body weight (2.5 mg/kg), administered as a single intramuscular injection in the neck. Note that the route of administration differs between species: subcutaneous for cattle and intramuscular for swine. The neck location is preferred for all species to minimize carcass trim losses at slaughter and to facilitate monitoring of injection site reactions. Following proper injection technique, including appropriate needle selection and aseptic practices, helps ensure drug delivery and minimize adverse effects.

The single-dose treatment protocol is one of tulathromycin's defining characteristics. Following injection, tulathromycin is rapidly absorbed and distributes extensively to lung tissue, where concentrations quickly exceed and remain well above plasma levels. The drug accumulates in pulmonary alveolar macrophages and other lung cells, creating a reservoir of antimicrobial activity in the primary site of respiratory infection. This tissue-targeting pharmacokinetic profile supports prolonged therapeutic activity from a single administration, eliminating the need for multi-day treatment regimens that increase animal handling and labor costs.

Proper injection technique is essential for optimal therapeutic outcomes. The injection site should be clean and dry, and aseptic technique should be employed. Needles of appropriate gauge and length should be selected based on animal size and the specified route of administration. For cattle, 16 to 18-gauge needles are commonly used for subcutaneous injection. For swine, similar gauge needles are appropriate for intramuscular injection. A maximum injection volume of 10 mL at any single site is recommended for cattle; larger doses should be divided between multiple injection sites. For swine, maximum volume per site is lower, proportional to the smaller body size.

For the treatment of infectious bovine keratoconjunctivitis (pinkeye), the same dose of 2.5 mg/kg is administered by subcutaneous injection. Early treatment when clinical signs are first recognized provides the best opportunity for resolution without permanent corneal damage. Animals with advanced disease or poor response to initial treatment may benefit from concurrent supportive care or consultation regarding alternative or additional therapies.

Withdrawal time requirements must be strictly observed for all treated animals destined for slaughter. For cattle, the meat withdrawal period is 18 days. For swine, the meat withdrawal period is 5 days. No animal should be slaughtered for human consumption before the expiration of the appropriate withdrawal period. Tulathromycin is not approved for use in female dairy cattle 20 months of age or older, as no milk withdrawal time has been established. Proper records documenting animal identification, treatment date, drug and dose administered, and calculated withdrawal date are essential for food safety compliance.

Tulathromycin is generally well-tolerated in both cattle and swine when administered according to label directions, with a safety profile that has contributed to its widespread adoption in food animal medicine. The most commonly observed side effects are injection site reactions, which are an expected consequence of parenteral drug administration in livestock. These local tissue responses are typically mild and transient, resolving without specific treatment over days to weeks following administration. The incidence and severity of injection site reactions are influenced by injection technique, needle selection, injection volume, and individual animal factors.

Injection site reactions in cattle may manifest as transient swelling, firmness, or mild inflammation at the site of subcutaneous administration. Clinical studies conducted for product registration documented these reactions in a proportion of treated animals, but the majority were classified as mild and resolved without intervention. The swelling typically peaks within the first few days following injection and gradually resolves over the subsequent one to two weeks. Proper injection technique, including appropriate site selection, needle gauge, and limiting injection volume per site, helps minimize local reactions. Administration in the neck region is required to avoid trim losses in valuable carcass cuts.

In swine, injection site reactions following intramuscular administration in the neck are similarly characterized by local swelling and tissue response. The intramuscular route in swine may produce somewhat different reaction patterns compared to subcutaneous administration in cattle, but the reactions are generally mild and self-limiting. Studies in swine have demonstrated good local tolerability. The neck injection site in swine, behind the ear, is selected specifically because this tissue is typically trimmed at slaughter, minimizing any carcass quality impact from persistent injection site lesions.

Systemic side effects following tulathromycin administration are uncommon. Transient decreases in feed intake and mild lethargy may occur in the 24 to 48 hours following treatment, though these effects are typically mild and resolve spontaneously. These nonspecific signs can be difficult to distinguish from the underlying respiratory disease process for which treatment was initiated. Gastrointestinal effects such as soft stool or minor digestive disturbances are possible with any antimicrobial that affects gut flora but are not commonly attributed to tulathromycin.

Serious adverse effects are rare with tulathromycin when used according to label directions in approved species. Hypersensitivity reactions, while possible with any drug, are not a prominent feature of tulathromycin's safety profile. The cardiovascular toxicity that characterizes some other macrolides in certain species has not been a significant concern with tulathromycin in either cattle or swine at approved doses. This favorable safety profile across both species distinguishes tulathromycin from older macrolides like tilmicosin, which causes fatal toxicity in swine.

Tulathromycin is contraindicated in animals with known hypersensitivity to the drug or to other macrolide antibiotics. While hypersensitivity reactions to macrolides are uncommon, any animal that has previously experienced an allergic or adverse response to tulathromycin or chemically related compounds should not receive the drug. Cross-reactivity between macrolide antibiotics is possible due to structural similarities within the drug class. Animals with documented adverse reactions to other macrolides such as tilmicosin, tildipirosin, gamithromycin, or tylosin should be carefully evaluated before tulathromycin administration.

The product is specifically contraindicated for use in female dairy cattle 20 months of age or older. This restriction effectively prevents use in lactating dairy cows and reflects the absence of an established milk withdrawal time for tulathromycin. Drug residues in milk represent both a public health concern and a regulatory violation with serious consequences for dairy operations. Dairy farms must have systems to identify and segregate animals to ensure that tulathromycin is never administered to cattle that will enter the milking herd. The 20-month age threshold captures essentially all cattle entering dairy production.

While tulathromycin has a broader species approval than some other macrolides, its use in species other than cattle and swine is not approved. Use in horses, sheep, goats, or other species would constitute extra-label use requiring careful veterinary evaluation. Unlike tilmicosin, tulathromycin has not been associated with fatal toxicity in horses or swine, providing greater flexibility for its use in multi-species operations. However, formal safety evaluation in non-approved species is limited, and extra-label use should be approached with appropriate caution.

Calves intended for veal production may be subject to additional restrictions depending on specific product labeling and veal quality assurance program requirements. The withdrawal period for tulathromycin in cattle is 18 days, which must be accommodated within the production timeline. Any use in veal calves requires assurance that the withdrawal period can be observed before the calf reaches its intended market date. Veterinary guidance is essential for treatment decisions in veal operations where withdrawal times may be a limiting factor.

Drug interactions involving tulathromycin include considerations common to the macrolide antibiotic class as well as some specific to food animal production systems. Concurrent administration of multiple macrolide antibiotics should be avoided, as this provides no additional therapeutic benefit while potentially increasing the risk of adverse effects. Animals receiving tulathromycin should not simultaneously receive tilmicosin, tildipirosin, gamithromycin, tylosin, or other macrolides. The extended tissue persistence of tulathromycin means that interactions could potentially occur with macrolides administered days after tulathromycin treatment.

The interaction between macrolide antibiotics and ionophore feed additives is an important consideration in cattle feeding operations. Ionophores including monensin, lasalocid, and laidlomycin are commonly included in cattle diets as growth promotants and for coccidiosis control. While specific interaction studies with tulathromycin and ionophores are limited, the potential for interaction warrants attention. Some macrolide-ionophore combinations have been associated with enhanced toxicity in certain circumstances. Consultation with a veterinarian regarding ionophore feeding programs during tulathromycin treatment is advisable, though tulathromycin appears to have a more favorable interaction profile than some older macrolides.

Theoretical considerations regarding bacteriostatic and bactericidal antimicrobial combinations apply to tulathromycin. As a macrolide, tulathromycin exhibits bacteriostatic activity by inhibiting bacterial protein synthesis. Concurrent use with bactericidal agents could theoretically result in reduced efficacy of the bactericidal drug. However, the clinical significance of this potential interaction in respiratory disease treatment is debated, and combination therapy is sometimes employed when multidrug-resistant infections are suspected or when multiple pathogens are involved. Veterinary judgment guides decisions about combination antimicrobial therapy.

When tulathromycin is used in combination with the anti-inflammatory drug ketoprofen, as in the Draxxin KP combination product, the drug interaction profile of ketoprofen must also be considered. Ketoprofen is a non-steroidal anti-inflammatory drug (NSAID) that can interact with other NSAIDs, corticosteroids, and potentially affect renal function. The combination product is specifically formulated and approved, but concurrent use of additional NSAIDs with Draxxin KP should be avoided. Consultation with a veterinarian is appropriate when considering treatment protocols that might involve multiple drug classes.

Human safety precautions apply to the handling and administration of tulathromycin, as with all veterinary injectable products. Direct contact with the product may cause skin and eye irritation. Handlers should wear appropriate personal protective equipment, including gloves and safety glasses, during product handling and administration. In the event of accidental skin contact, the affected area should be washed with soap and water. Accidental eye exposure should be addressed by immediately flushing the affected eye with clean water for at least 15 minutes, and medical attention should be sought if irritation persists.

Accidental self-injection is a potential hazard with any injectable veterinary product. Care should be exercised during animal restraint and drug administration to minimize the risk of accidental needlestick injuries. In the event of accidental self-injection, medical attention should be sought and the healthcare provider informed that the product is a macrolide antibiotic. While tulathromycin does not carry the same level of human toxicity concern as tilmicosin, accidental injection warrants medical evaluation to assess and manage any local or systemic effects. Persons with known hypersensitivity to macrolide antibiotics should exercise particular caution to avoid exposure.

Food safety and residue avoidance are paramount considerations in food animal antimicrobial use. The established withdrawal periods of 18 days for cattle and 5 days for swine must be strictly observed for all treated animals destined for human consumption. No animal should be slaughtered before the withdrawal period has elapsed. Proper identification of treated animals, accurate record-keeping, and clear communication between treatment and marketing personnel are essential components of residue prevention programs. Operations should have systems in place to ensure that withdrawal status is tracked and that no animals are sent to slaughter prematurely.

Antimicrobial stewardship requires that tulathromycin be used judiciously and only when bacterial infection is diagnosed or reasonably suspected. Indiscriminate antimicrobial use promotes the selection of resistant bacteria, potentially compromising future treatment options. Tulathromycin should be part of a comprehensive health management program that includes appropriate biosecurity, vaccination protocols, nutrition management, and environmental controls to minimize disease incidence. When treatment is necessary, proper drug selection, accurate dosing, and appropriate case selection help preserve antimicrobial efficacy for future use.

Environmental considerations govern the proper disposal of unused product and associated materials. Tulathromycin should be disposed of in accordance with federal, state, and local regulations. The drug should not be discharged into waterways or sewage systems. Empty containers should be disposed of according to label directions. Sharps including needles and syringes should be placed in approved puncture-resistant containers and managed as regulated medical waste. Responsible disposal practices protect the environment and reduce the risk of accidental exposure.

Tulathromycin should be stored at controlled room temperature between 20°C and 25°C (68°F to 77°F), with permitted temperature excursions between 15°C and 30°C (59°F to 86°F) during transport and handling. The product should be protected from freezing and from prolonged exposure to direct light. In farm and feedlot settings where ambient temperatures may vary considerably, storage in climate-controlled areas helps maintain product quality. Product that has been frozen should not be used, as freezing may alter the formulation's characteristics and potentially affect drug delivery and efficacy.

Multi-dose vial handling requires attention to aseptic technique to maintain product sterility and prevent contamination. The rubber stopper should be disinfected with alcohol before each needle entry. Clean, sterile needles should be used for each entry into the vial, and needles should be changed between animals to prevent disease transmission and vial contamination. Once broached, multi-dose vials should be used within a reasonable timeframe, typically within 28 days unless otherwise specified on the product label. Before each use, the vial contents should be visually examined for any signs of particulate matter, cloudiness, discoloration, or other changes. Product showing such changes should not be used.

Disposal of tulathromycin containers, unused product, and administration equipment should comply with all applicable regulations. Empty containers should be triple-rinsed before disposal or recycling according to label instructions. Unused or expired product should not be disposed of through regular trash collection or household drains due to potential environmental impacts. Many areas have pharmaceutical take-back programs or approved disposal facilities for veterinary medications. Sharps including needles and syringes must be placed in approved puncture-resistant sharps containers and disposed of according to local regulations for medical waste. Proper disposal prevents environmental contamination and reduces the risk of accidental human or animal exposure to pharmaceutical residues.

Tulathromycin dosing is consistent across all cattle and swine breeds at 2.5 mg/kg body weight, without breed-specific dose adjustments. Clinical studies supporting product approval included animals representing the diversity of commercial cattle and swine genetics, establishing efficacy and safety across commonly encountered breeds and genetic lines. Whether treating Angus, Hereford, Charolais, Holstein, or any of the numerous other cattle breeds and crosses, or various commercial swine genetics, the same weight-based dosing recommendation applies. Accurate body weight determination remains the critical factor in ensuring appropriate dosing regardless of breed.

Breed-related differences in disease susceptibility and production characteristics may influence how tulathromycin is used in practice, even though dosing does not change. Some cattle breeds or types are recognized as having different respiratory disease susceptibility, whether due to inherent physiological factors, typical management systems, or selection history. For example, lightweight cattle from auction markets may face different BRD challenges than heavier calves weaned and backgrounded on their ranch of origin. These differences influence metaphylactic treatment decisions and case selection rather than drug dosing per se.

Production system considerations often correlate with breed type in ways that affect tulathromycin use patterns. Feedlot populations commonly include various beef breed crosses and dairy-beef animals, each facing the intense respiratory disease pressure of the receiving period. Cow-calf operations use tulathromycin primarily for treatment of clinical BRD or pinkeye in individual animals. Stocker and backgrounding operations represent intermediate situations with variable disease pressure depending on cattle source and management. In swine, different production systems and genetic programs may have different respiratory disease challenges, though tulathromycin use is guided by disease presence rather than genetics.

Age and weight considerations apply across all breeds and represent more important variables than breed identity for tulathromycin use decisions. Very young animals may have different disease susceptibility and treatment needs compared to older stock. Nursing calves, weaned calves, and yearling cattle represent distinct populations from a respiratory disease perspective. Similarly, suckling pigs, nursery pigs, and finishing pigs face different challenges. Accurate weight determination is essential for proper dosing at all ages, and weight can be particularly challenging to estimate accurately in young, rapidly growing animals.

Within the macrolide antibiotic class, several alternatives to tulathromycin are available for respiratory disease treatment in food animals. Gamithromycin (Zactran) is another single-dose macrolide approved for cattle with a similar pharmacokinetic profile of prolonged lung tissue concentrations. Tildipirosin (Zuprevo) is approved for both cattle and swine, offering another macrolide option for operations with both species. Tilmicosin (Micotil) is an older macrolide effective in cattle but carries the critical limitation of being fatally toxic to swine and horses, making it unsuitable for many mixed-species operations where tulathromycin's broader species safety is advantageous. Tylosin (Tylan) represents an older macrolide with a long history of use in both species, though its typical applications differ somewhat from acute respiratory disease treatment.

Alternative drug classes provide options when macrolide therapy is not appropriate or when pathogen resistance patterns suggest other choices may be more effective. Florfenicol (Nuflor) offers broad-spectrum activity including efficacy against some macrolide-resistant bacteria. Fluoroquinolones including enrofloxacin (Baytril) and danofloxacin (Advocin) provide bactericidal options with good respiratory tract penetration. Ceftiofur (Excede, Excenel) represents cephalosporin options with extended-spectrum gram-negative activity. Tetracyclines including oxytetracycline maintain a role in respiratory disease treatment, particularly in combination protocols or situations where cost is a significant factor.

Combination products and treatment protocols may incorporate tulathromycin as part of comprehensive respiratory disease management. The Draxxin KP combination product provides both tulathromycin and the NSAID ketoprofen, addressing the infectious and inflammatory components of BRD simultaneously. In some treatment protocols, antimicrobials may be combined with supportive care including anti-inflammatories, rehydration, and environmental modifications. The selection of treatment approach should be guided by disease severity, pathogen susceptibility, previous treatment history, cost considerations, and withdrawal time requirements. Veterinary consultation helps optimize treatment decisions based on the specific situation and available options.